apoptosis is only observed at higher drug concentrations. FdAinduced apoptosis seems to be most effectively induced by phosphorylated p53, but can still occur in its absence. Elucidation of the molecular mechanism of p53-independent apoptosis may provide potential strategies for overcoming drug resistance.
Raji and MEC1 cells contain different molecular weight forms of p53 (Figure 2e ). Raji cells probably have the unmutated form of p53 (B53 kDa, pI B6.4 in unphosphorylated form, Figures 2a and b) and MEC1 cells express a truncated version of p53 of B48 kDa with a more acidic pI (Figures 2c-e) . Furthermore, initial levels of p53 in MEC1 cells are much lower than in Raji cells. One of the best-described derivatives of p53 is p47, lacking the 40 N-terminal amino acids of p53 that become phosphorylated in response to DNA damage. 8 p47 cannot be activated upon genotoxic stress and has impaired transcriptional activation capacity. However, the antibody used for detection of p53 here recognizes an N-terminal epitope (amino acids 11-25); therefore the truncated form of p53 expressed in MEC1 cells must contain some of the original N terminus of p53. The different responses of nuclear p53 in MEC1 and Raji cells treated with FdA suggest that the resistance of MEC1 cells could arise from a truncation mutation or splice variant of p53. More than 50% of all cancers have mutations in p53, the most common oncogene; 10-15% of all CLL have mutated p53. The MEC1 cells, derived from a B-CLL patient, are likely to contain a deletion mutation in p53 that could provide resistance to FdA. Despite retaining the N-terminal epitope, the truncated p53 in MEC1 cells was not phosphorylated and did not accumulate during FdA treatment. This mutant form of p53 in MEC1 cells has not been described; sequencing the mutated p53 gene may provide an explanation for the resistance to fludarabine. The JAK2V617F mutation has recently been described as an essential oncogenetic event associated with the myeloproliferative disorders (MPD). 1 Several techniques have emerged to detect this kind of mutation. As a newly developed one, MassARRAY assay combines competitive PCR with MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight) mass spectrometry and is an advanced system for automated highthroughput analysis of mutations or single nucleotide polymorphisms (SNPs). 2 Other methods of SNPs detection, which previously reported suitable for JAK2V617F mutation, included restriction fragment length polymorphism (RFLP), 3 direct sequencing analysis, 4 pyrosequencing, 5 real-time AS-PCR 6 and a denaturing high-performance liquid chromatography (DHPLC) assay. 7 RFLP analysis is the simplest and cheapest method, not requiring specific instruments. Although it can be used as the first screening method for JAK2V617F mutation, there may be false positives because of incomplete digestion, 3 and positive results need to be confirmed by another detection system. Direct sequencing analysis is a golden rule of SNP detection with high specificity and can identify any unknown SNP, providing detailed information and 'direct visualization' of sequence information. However, the sensitivity of sequencing is rather low (45%), its laborious, time-consuming and expensive procedure needs no mention. 4 Pyrosequencing is a quantitative and rapid method, presenting sequence data 'in real time' without post-PCR procession. But it is also not sensitive enough (5-10%). 5 Real-time AS-PCR is a more sensitive method (0.1%) for allele-specific real-time quantification, while the design of the primer and probe is complex and each lab needs an individual cutoff point for analyzing any SNPs, otherwise the false positives might occur. 6 The DHPLC assay also needs post-PCR procession, thus elaborating and technically challenging. 7 Here, we developed an accurate, sensitive and highthroughput MassARRAY assay for detecting JAK2V617F mutation. In our study, 162 patients with MPD were screened using both BsaXI restriction analysis and MassARRAY assay. BsaXI restriction analysis was performed and evaluated as reported by Campell et al. 2 For the MassARRAY assay, the PCR primers and extension primers were designed by MassARRAY Assay Design 2.0 Software. To provide a significant improvement in overall performance, 10-mer tag (5 0 -ACGTTGGATG-3 0 ) was added to the 5 0 ends of each PCR primer: 2nd-PCRP: 5 0 -ACGTTGGATG
0 . The polymorphic loci were PCR amplified on a 384-well plate in a volume of 5 ml mixture as previously described. 7 The PCR products were then purified with shrimp alkaline phosphatase and mixed with 2 ml primer extension mixture, including 9 mM extension primer: 5 0 -ACTCTCGTCTCCACAGA-3 0 , 0.018 ml thermosequenase and 0.2 ml 10 Â Termination Mix of ddCTP, ddGTP, ddTTP and dATP (suitable for the G4T variation of JAK2V617F) (Amersham Biosciences, Uppsala, Sweden). After desalting procedure, the reaction products were transferred onto a 384-well SpectroCHIP and analyzed by the MassARRAY Analyser(Sequenom, San Diego, CA, USA). To assess the sensitivity of this assay, the dilution series of wild-type and mutant DNA was performed separately. Both of them could be detected even at 1:10 000 dilution (containing 0.01% wild-type or mutant DNA, Figures 1a  and b) . To simulate the conditions in patients, dilutions of wildtype and mutant DNA were further prepared. When diluted with mutant DNA, wild-type DNA was still detectable at the sensitivity of 1% (wild-type: mutant DNA ¼ 1%, Figure 1c ). In the series of mutant diluted with wild-type DNA, the sensitivity was 5% (mutant: wild-type DNA ¼ 5%, Figure 1d ). The decrease of sensitivity may probably be due to the competitive activity between wild-type and mutant DNA, resulting in mutual interference based on PCR technique.
By MassARRAY assay, JAK2V617F mutation was detected in 92 of 162 (56.8%) MPD patients (81 patients with heterozygous mutation and 11 patients with homozygous mutation), including 49 of 59 (83.1%) polycythemia vera (PV) cases, 34 of 61 (55.7%) essential thrombocythemia cases, 9 of 13 (69.2%) idiopathic myelofibrosis cases, but none in chronic myelomonocytic leukemia (n ¼ 9) and hypereosinophilic syndrome (n ¼ 20) cases. Meanwhile, no JAK2V617F mutation was found in bcr/ abl positive chronic myeloid leukemia (n ¼ 96), myelodysplastic syndrome (n ¼ 30), acute myeloid leukemia (n ¼ 30) patients, or healthy volunteers (n ¼ 15). The positive frequency was lower than that of BsaXI restriction analysis (97 of 162, 59.9%; 59 patients with heterozygous mutation and 38 patients with homozygous mutation). Among 24 cases with conflicting results, direct sequencing analysis was further performed, 17 patients had the same profile as MassARRAY assay. In the remaining seven patients, although heterozygous mutations were revealed by MassARRAY assay, homozygous mutations were both detected by BsaXI restriction and direct sequencing analysis. Further AS-PCR succeeded in amplifying JAK2 transcripts using both wild-type-(5 0 -TTTGGTTTTAAATTATGGA GTATGTG-3 0 and 5 0 -AAAGGCCAGTTATTCCAATGTTATG-3 0 ) and mutant-specific primers (5 0 -TTTGGTTTTAAATTATGGAGT ATGTTTC-3 0 and 5 0 -AAAGGCCAGTTATTCCAATGTTATG-3 0 ). Subsequently, purified PCR products were ligated into pGEM-T Easy Vector (Promega Corporation, Madison, WI, USA) and clone sequencing analysis was also performed. Wild-type clones were found in 1/19, 2/25, 1/20, 1/12, 1/11, 1/15 and 2/ 11 clones, respectively. These results confirmed the heterozygous mutations, demonstrating that the MassARRAY assay was more sensitive and accurate than BsaXI restriction and Letters to the Editor direct sequencing analysis. Representative results were shown in Figure 2 . Technically, the MassARRAY assay was based on the annealing of an extension primer adjacent to the SNP of interest, which generates allele-specific extension products with a unique molecular mass. It can detect the molecules of pmol or fmol levels and recognize the difference of less than five copies with only 2-5 ng DNA as template. Consequently, heterozygote and homozygote could be recognized more accurately. 2 The analysis is highly specific and reproducible. Besides, it can detect up to 12 SNPs in each sample, while most of the methods used in JAK2V617F detection mentioned above are used for unique variation detection. It is a high-throughput technology and can detect 384 samples at the same time, greatly reducing the cost for each sample.
Among the clinical features, no differences of sex and age were found between MPD patients positive and negative for JAK2V617F mutation. Interestingly, comparing with wild-type cases, PV patients with homozygous mutation presented a significant elevation of white blood cell counts (30.878.0 Â 10 9 l À1 vs 9.071.4 Â 10 9 l À1 , P ¼ 0.005). Moreover, higher hemoglobin concentration was found in the cases with heterozygous mutation (183.175.3 g l À1 ) than those with wildtype (150.2715.7 g l À1 , P ¼ 0.014). In vitro, erythropoietin hypersensitivity was induced in murine hematopoietic cells transduced with JAK2V617F. 8 In vivo, expression of JAK2V617F in a murine bone marrow transplant model developed features of PV. 8 Therefore, this mutation could cause abnormal proliferation of hematopoietic progenitors and related to PV pathogenesis.
Taken together, JAK2V617F mutation could be a molecular marker in the diagnosis of MPD patients. The MassARRAY technique is a method with precision and accuracy in JAK2V617F detection. 
